-
![4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors](/abs-image/US/2021/06/08/US11028093B2/abs.jpg.150x150.jpg)
公开(公告)号：US11028093B2
公开(公告)日：2021-06-08
申请号：US16890663
申请日：2020-06-02
Applicant: Array BioPharma Inc. , Celgene Corporation
Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: A61K45/06 , C07D487/04 , A61K31/4985 , A61K31/5377
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
![4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS](/abs-image/US/2017/12/21/US20170362240A1/abs.jpg.150x150.jpg)
公开(公告)号：US20170362240A1
公开(公告)日：2017-12-21
申请号：US15532937
申请日：2015-12-04
Applicant: ARRAY BIOPHARMA INC. , CELGENE CORPORATION
Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06
CPC classification number: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
![5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES](/abs-image/US/2014/08/14/US20140228349A1/abs.jpg.150x150.jpg)
公开(公告)号：US20140228349A1
公开(公告)日：2014-08-14
申请号：US14351415
申请日：2012-10-09
Applicant: Array BioPharma Inc.
Inventor： Mark Laurence Boys , Laurence E. Burgess , C. Todd Eary , Robert Groneberg , Bruno P. Hache , Darren Harvey , Erik James Hicken , Christopher F. Kraser , Ellen Laird , David A. Moreno , Mark C. Munson , Li Ren , John E. Robinson , Stephen T. Schlachter
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3, R4, R5, R6, X1 and X2 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
Abstract translation: R 1，R 2，R 3，R 4，R 5，R 6，X 1和X 2具有本说明书中给出的含义的式I化合物及其立体异构体及其药学上可接受的盐和溶剂化物是一种或多种JAK激酶的抑制剂，并且是有用的 治疗自身免疫性疾病，炎症性疾病，移植器官，组织和细胞排斥，以及血液系统疾病和恶性肿瘤及其并发症。
-
公开(公告)号：US09221841B2
公开(公告)日：2015-12-29
申请号：US14663286
申请日：2015-03-19
Applicant: Array BioPharma Inc.
Inventor： Jeremy Hans , Eli M. Wallace , Qian Zhao , Shelley Allen , Ellen Laird , Joseph P. Lyssikatos , John E. Robinson , Christopher P. Corrette , Robert Kirk DeLisle , Walter C. Voegtli
IPC: C07D417/04 , C07D417/14 , C07D285/12 , C07D471/04 , C07D419/04 , C07D487/04 , C07D513/04 , C07D495/04 , C07F9/6539 , C07D497/04
CPC classification number: C07D513/04 , C07D285/12 , C07D417/04 , C07D417/14 , C07D419/04 , C07D471/04 , C07D487/04 , C07D495/04 , C07D497/04 , C07F9/65395
Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
Abstract translation: 本发明涉及有丝分裂驱动蛋白抑制剂，特别是KSP，以及制备这些抑制剂的方法。 本发明还提供包含本发明抑制剂的药物组合物和利用抑制剂和药物组合物治疗和预防各种疾病的方法。
-
公开(公告)号：US20140045817A1
公开(公告)日：2014-02-13
申请号：US14057882
申请日：2013-10-18
Applicant: Array BioPharma Inc.
Inventor： Shelley Allen , Laura L. Celeste , T. Gregg Davis , Robert Kirk DeLisle , Julie Marie Hicks , Stefan D. Gross , Erik James Hicken , Leila J. Jackson , Nicholas C. Kallan , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , Jed Pheneger , Bryson Rast , John E. Robinson , Stephen T. Schlachter , George T. Topalov , A. Dale Wright , Qian Zhao
IPC: C07D471/04 , C07D451/06
CPC classification number: C07D471/04 , A61K31/437 , C07D451/06 , C07D519/00
Abstract: Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.
Abstract translation: 本文提供了一种在哺乳动物中治疗PIM-1和/或PIM-3和/或PIM-3激酶介导的病症的方法，其包括向所述哺乳动物施用治疗有效量的式I化合物：其中 A，B，R1，R1a，R2，R3，R4，R5，R6和R7具有说明书中给出的含义。
-
Patent Agency Ranking
公开(公告)号：US20150191490A1
公开(公告)日：2015-07-09
申请号：US14663286
申请日：2015-03-19
Applicant: Array BioPharma Inc.
Inventor： Jeremy Hans , Eli M. Wallace , Qian Zhao , Shelley Allen , Ellen Laird , Joseph P. Lyssikatos , John E. Robinson , Christopher P. Corrette , Robert Kirk Delisle , Walter C. Voegtli
IPC: C07D513/04 , C07D285/12 , C07D417/04 , C07D419/04 , C07D497/04
CPC classification number: C07D513/04 , C07D285/12 , C07D417/04 , C07D417/14 , C07D419/04 , C07D471/04 , C07D487/04 , C07D495/04 , C07D497/04 , C07F9/65395
Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
Abstract translation: 本发明涉及有丝分裂驱动蛋白抑制剂，特别是KSP，以及制备这些抑制剂的方法。 本发明还提供包含本发明抑制剂的药物组合物和利用抑制剂和药物组合物治疗和预防各种疾病的方法。
-
公开(公告)号：US20140018399A1
公开(公告)日：2014-01-16
申请号：US14031958
申请日：2013-09-19
Applicant: Array BioPharma Inc.
Inventor： Jeremy Hans , Eli M. Wallace , Qian Zhao , Shelley Allen , Ellen Laird , Joseph P. Lyssikatos , John E. Robinson , Christopher P. Corrette , Robert Kirk DeLisle , Walter C. Voegtli
IPC: C07D285/12 , C07D417/04
CPC classification number: C07D513/04 , C07D285/12 , C07D417/04 , C07D417/14 , C07D419/04 , C07D471/04 , C07D487/04 , C07D495/04 , C07D497/04 , C07F9/65395
Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
Abstract translation: 本发明涉及有丝分裂驱动蛋白抑制剂，特别是KSP，以及制备这些抑制剂的方法。 本发明还提供包含本发明抑制剂的药物组合物和利用抑制剂和药物组合物治疗和预防各种疾病的方法。
-
![4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS](/abs-image/US/2019/06/13/US20190177328A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190177328A1
公开(公告)日：2019-06-13
申请号：US16212493
申请日：2018-12-06
Applicant: Array BioPharma Inc. , Celgene Corporation
Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: C07D487/04 , A61K45/06 , A61K31/4985 , A61K31/5377
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
![4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors](/abs-image/US/2019/01/29/US10189845B2/abs.jpg.150x150.jpg)
公开(公告)号：US10189845B2
公开(公告)日：2019-01-29
申请号：US15532937
申请日：2015-12-04
Applicant: ARRAY BIOPHARMA INC. , CELGENE CORPORATION
Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett
IPC: A61K45/06 , C07D487/04 , A61K31/4985 , A61K31/5377
Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
-
公开(公告)号：US08987251B2
公开(公告)日：2015-03-24
申请号：US14057882
申请日：2013-10-18
Applicant: Array BioPharma Inc.
Inventor： Shelley Allen , Laura L. Celeste , T. Gregg Davis , Robert Kirk DeLisle , Julie Marie Hicks , Stefan D. Gross , Erik James Hicken , Leila J. Jackson , Nicholas C. Kallan , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , Jed Pheneger , Bryson Rast , John E. Robinson , Stephen T. Schlachter , George T. Topalov , A. Dale Wright , Qian Zhao
IPC: A61K31/437 , C07D471/04 , C07D451/06 , C07D519/00
CPC classification number: C07D471/04 , A61K31/437 , C07D451/06 , C07D519/00
Abstract: Provided herein is a method of treating a PIM-1 and/or PIM-2 and/or PIM-3 kinase-mediated condition in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification.
Abstract translation: 本文提供了一种在哺乳动物中治疗PIM-1和/或PIM-3和/或PIM-3激酶介导的病症的方法，其包括向所述哺乳动物施用治疗有效量的式I化合物：其中 A，B，R1，R1a，R2，R3，R4，R5，R6和R7具有说明书中给出的含义。
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.027 seconds)
